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ABSTRACT 
The aim of this study is to develop electrospun gelatin nanofibers based drug delivery carrier to 
achieve controlled and sustainable release of hydrophobic drug (piperine) for prolonged time. To 
accomplish this, we devised some strategies such as sandwiching the drug loaded gelatin 
nanofiber mesh with another gelatin nanofiber matrix without drug (acting as diffusion barrier), 
sequential crosslinking and finally, a combination of both. As fabricated multilayered 
electrospun nanofibers mesh was first characterized in terms of degradation study, morphology, 
drug-polymer interactions, thermal stability followed by studying their release kinetics in 
different physiological pH as per the gastrointestinal tract. Our results show that with optimized 
diffusional barrier support and sequential crosslinking together, a zero order sustained drug 
release up to 48 h may be achieved with a flexibility to vary the drug loading as per the 
therapeutic requirements. This work lays out the possibility of systematic design of multilayer 
nano-fiber mesh of a biopolymer as a drug delivery vehicle for hydrophobic drugs with a desired 
signature of zero order release for prolonged duration.   
Keywords: Gelatin nanofiber; Hydrophobic drug; Zero order release; Crosslinking; Multi-layers 
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1. Introduction 
Over the years, researchers have engineered different drug-delivery vehicles to maintain 
the drug concentration in the body within its therapeutic range for prolonged time [1-8]. 
Electrospun nanofiber is also one of such systems that have dragged lot of attentions in 
recent past. Exceptional properties of such fibers, e.g. highly porous three dimensional 
surface, high surface-to-volume ratios, interconnected porosity with tuneable pore 
dimensions, found tremendous applications in different biomedical fields [9-15]. Various 
electrospinning parameters modulate the fiber diameter and thickness, which may affect 
sustained and controlled release profiles [16-18]. To increase the diffusional path between 
the drug and dissolution medium, eventually the concept of multi-layered electrospun 
fibers was developed, which enabled better control in release [13, 14]. The idea behind 
preparing multi-layered electrospun mesh is to get sustained molecular release for a 
prolonged time by controlling the drug mobility. By sandwiching the drug loaded layer 
between two adjacent electrospun layers, one can control the kinetics of water uptake, 
which in turn promotes the sustained release of drug molecules through precise control in 
both degradation as well as osmotic pressure [13, 14]. However to the best of our 
knowledge, there is no such study being performed for hydrophobic drugs, delivery of 
which is a challenge for any biodegradable polymer. 
In our previous work, we fabricated single layered piperine loaded (model hydrophobic 
drug) electrospun gelatin nanofibers (GNF) mesh, and achieved sustained release to some 
extent as per the gastrointestinal (GI) tract, by controlling the swelling and crosslinking 
[19].  Due to the highly porous structure of nanofibers, we have crosslinked GNF using 
saturated vapor of gluteraldehyde (GTA) because of its tremendous capability to crosslink 
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within a short time span [19]. We were able to crosslink the mesh by only a few minutes 
of GTA exposure (6 min) instead of a few hours or even days as reported in literature [20-
22]. This might reduce the risk of toxicity caused by GTA. Results showed a typical two 
stage, curved profile for all the cases i.e. a sudden release of drugs during initial hours 
followed by a much slower release during the rest of the observation time scale. The 
probable reason for this kind of common release pattern could be the penetration of water 
molecules in the mesh which caused swelling of the matrix. Due to swelling, the drug 
molecules from the outer layers started releasing rapidly, which caused sudden release (65 
%) of drug molecules from 6 min crosslinked mesh (G-P NF C6) within 4 h in pH 7.4 
[19]. This kind of profile can be used for specific treatment purpose where initial release 
of drug is required. However in general, this type of release profile potentially can cross 
the toxic drug-concentration level within initial hours and sub therapeutic drug 
concentration in later part [23]. As piperine is the most formidable bio-enhancer till date, 
it helps to enhance the bio-availability of other drugs by boosting the absorption from the 
intestine [24]. It also has anti-microbial, anti-inflammatory, anti-depressant, anti-
cancerous effects [25-27] apart from being hydrophobic in nature. This motivated us to 
further modify our electrospun GNF vehicle by introducing multi-layered sandwiched 
mesh structure, so that it can achieve close to zero order/controlled release in intestine. 
Here, piperine was incorporated into sandwiched GNF mesh with variations in barrier and 
core layer thicknesses. The effect of drug concentration and sequential crosslinking on 
release profile was also investigated. In addition to that, controlling the mobility of 
hydrophobic drug molecules through hydrophilic polymer matrix is also challenging [19]. 
Therefore, the objective of this work is to regulate the release profiles in such way so that 
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we can achieve almost zero order release (without initial burst release) of piperine (a 
model hydrophobic drug) for nearly 48 h from this newly developed vehicle. 
 
2. Materials and methods 
2.1. Materials 
Gelatin (Type A, 175 bloom), piperine (98%), hydrochloric acid (ACS, 36.5-38.0%), 
gluteraldehyde (25% v/v aqueous solution), acetic acid (glacial, ACS, ~99.7%), sodium 
hydroxide pallets (98%), phosphate buffer saline (pH 7.4) were purchased from Alfa 
Aesar. Deionized water (DI) (Milli Q, resistivity 18.1 MΩ.cm) was used throughout the 
experiments. 
2.2. Fabrication of nanofiber membrane 
Multi-layered meshes were prepared by electrospinning 20% (w/v) of Gelatin (Type A) 
solution in acetic acid (20% v/v in distilled water) solvent using electrospinning apparatus 
(Make: E Spin Nanotech Pvt. Ltd, India). Then a known amount of piperine was added to 
spinning solution for drug loaded samples (G-P NF). Multi-layered GNF was prepared by 
sequential eletrospinning of with and without drug loaded solutions on the substrate 
(aluminium foil). The samples were then crosslinked using saturated vapor of GTA (25% 
v/v aqueous solution) for few minutes (6 and 8 min; i.e. G-P NF C6 and G-P NF C8 
respectively) [19]. 
2.3. Characterization  
The morphology of the fibers was examined by table top Scanning Electron Microscopy 
(SEM) (Make: Phenom world ProX, Netherlands). To reduce the charging effect, samples 
were coated with thin gold layer using sputter coater (DC Sputtering system, Make: Excel 
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Instruments, India). In-vitro degradation studies were then carried out to check the 
stability of the crosslinked membranes (G-P NF C6 and G-P NF C8) in PBS (pH 7.4) at 
37 
0 
C for 48 h. The weight loss (WL %) due to hydrolytic degradation is calculated by 
using the following equation [9]: Weight loss (WL %) =    
  
  
      Where, Mf = 
Sample mass after an incubation period. Mi = Initial sample mass. Similarly, Swelling 
degrees (SD) were calculated using the following equation [9]: Swelling degree (SD %) = 
       
  
     ; where, Ws = Weight of swelled sample and Wd = Initial weight of dried 
sample.  To investigate the stability of the drug and the effect of cross-linking on the 
mesh, samples were characterized by Fourier transform infra-red spectroscopy (FTIR, 
Bruker Tensor 37, USA) in 400-4000 cm
-1
 range with a resolution of 4 cm
−1
 and 256 
scans per samples. Thermal stability of the vehicle was investigated by thermogravimetric 
analysis (TGA) (Model: Pyris 1, PerkinElmer Inc., USA) in helium atmosphere in the 
range to 35 to 600 
0 
C at a heating rate of 10 
0 
C/min. Finally, in-vitro release of the drug 
i.e., piperine from multi-layered G-P NF, meshes were analysed using UV–vis 
spectroscopy (Lambda 35 Perkin Elmer, USA) at 342 nm i.e. the λmax for piperine [19]. 
To investigate the drug release kinetics and mechanism, the in-vitro release data were 
analysed using zero order equation [23]. 
 
3. Results and discussion 
3.1. Surface morphology analysis 
The primary challenge of most of the drug-delivery systems is to achieve nearly zero 
order release profile for prolonged duration. To meet such requirements using GNF, 
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multi-layered mesh was fabricated and finally examined in terms of morphology, water 
resistivity, degradation, chemical and thermal stability as well as release studies. 
The surface morphology of electrospun G-P NF, G-P NF C6, G-P NF C8 samples are 
represented in Fig.1. Randomly oriented continuous piperine loaded gelatin nanofibers 
are presented in Fig.1a. Nanofiber mesh is highly porous structure and gelatin is highly 
soluble in water. Due to such high ratio of surface area to volume, this kind of porous 
structure with large surface area will immediately dissolve in contact of water molecules 
in any types of aqueous solutions. Thus for crosslinking the gelatin fiber, we used 
saturated vapor of the same solution (25% v/v aqueous solution of GTA) to minimize the 
water related degradation of gelatin fibers. Here, the membranes are thus crosslinked with 
saturated vapor of GTA for 6 and 8 min, presented in Fig.1b and 1c. Water molecules 
present in saturated vapor have partially degraded the fibers and fused them together 
shown in Fig.1b and 1c (more compact morphology). The partial degradation due to 
swelling of fibers is commonly visible in case of gelatin nanofibers which are reported in 
our previous work [19]. Due to the presence of hydrophobic molecules (piperine in this 
case) in the gelatin mesh, the fusions of fibres are substantially less. This fused structure 
of nanofiber membrane can tailor the release of drug molecules to the release medium.  
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Fig. 1. Morphology of the electrospun fiber membrane of a) G-P NF, b) G-P NF C6 and 
c) G-P NF C8 
   
3.2. In-vitro degradation study analysis 
To understand the effect of crosslinking on G-P NF samples in-vitro degradation study 
and swelling study were performed in PBS (pH 7.4: mimicking physiological pH of 
intestine) only for 50 h (Fig. 1S). Although, the crosslinked mesh need to sustain a period 
of maximum 4 h in pH 1.2 (mimicking physiological pH of stomach), we checked the 
stability for 24 h in our previous work [19]. Results showed that G-P NF C6 was 
reasonably stable in aqueous medium for a period of 50 h and therefore considered for 
further studies. In summary, we have successfully crosslinked the mesh with minimal 
exposure in GTA vapor which can sustain more than 2 days in physiological pHs.    
3.3. Thermal and chemical stability analysis  
TGA thermograms of samples showed two stages of weight loss inside the overall range 
of 35-700 
0
C and are presented in supplementary section (Fig. 2S). Weight loss for G-P 
NF C6 was found to be less in compare to G-P NF, which is an indication of improved 
thermal stability upon crosslinking. 
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After checking thermal stability, chemical stability of drug loaded gelatin nanofiber 
fabricated vehicle was also investigated. To understand the crosslinking effects on 
nanofibers and the co-existence of both drug and polymer with their own characteristic 
identify, FTIR was performed and results were presented in supplementary section as Fig. 
4S [19]. The shifting of peaks near amide I, II and III as an after-effect of 6 min 
crosslinking were also reported [19]. Comparison between pure gelatin fiber and piperine 
loaded gelatin fibers were detailed in previous work [19]. In a nut shell, the presence of 
amide peaks of gelatin around 1628 cm
-1 
and aliphatic C-H stretching of piperine around 
2920.71cm
-1
 proves chemical stability of piperine in gelatin nanofiber mesh.   
3.4. In-vitro release study analysis 
After investigating the different aspects of the vehicles such as: the drug-polymer interactions, 
thermal stability, swelling and degradation in aqueous medium, in-vitro drug release was done in 
order to design a nanofiber based vehicle which can provide a constant drug release for a prolong 
period of time.  
3.4.1.Designing the carrier:  
The intention of this study was to develop a drug delivery vehicle, which can provide a near to 
zero order release profile in different physiological pH. Thus, we started modifying our existing 
single layered vehicle which can successfully circumvent the two stage release profile.  
 (a) Effect of multi-layer in release profile  
First, we attempted to design a vehicle with sufficient diffusional barrier which can exhibit a 
close to zero order release without initial fast release of drug molecules. To meet the 
aforementioned release profile for the cases with appreciable drug loading, we fabricated 
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different types of sandwiched structured multi-layered mesh by coating drug loaded layers by 
two sequential layers of gelatin as shown in Fig. 2 and Table 1.  
 
Fig. 2: Schematic presentation different composition of sandwiched nanofiber mesh. 
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Table 1: Summary of the configuration of sandwiched electrospun nanofiber membrane  
 
Cases 
 
Composition 
G-(G+P)-G (layers) 
(ml) 
 
Remarks based on the drug release 
profiles (Fig. 3a) 
 
A: G-P NF C6/4/0.5 
 
(0.5+4+0.5)=5ml 
1. G Barrier is very less (0.5 ml). 
2. G+P is sufficient (4 ml) 
B: G-P NF C6/3/1 (1+3+1)=5ml 1. G Barrier better than A. 
C: G-P NF C6/2/1.5 (1.5+2+1.5)=5ml 1. G Barrier is improved (1.5 ml) 
2. G+P is less (2 ml) 
D: G-P NF C6/1/2 (2+1+2)=5ml 1. Good diffusional barrier (2 ml) 
2. Very less drug loading (1 ml) 
E: G-P NF C6/4/2 (2+4+2)=8ml 1. Combining A and D 
2. Good amount of drug loading (4ml) 
3.Sufficiant diffusional barrier (2ml) 
F: G-P NF C6/4/3 (3+4+3)=10ml 1. Further improved sample E by adding 
extra diffusional barrier (3ml) 
2. Drug loading is same (4ml) 
 
As a starting point, 5 ml of polymer solution was deposited to fabricate four different 
sandwiched structure i.e. A to D (Table 1 and Fig. 2). Fig. 3a showed initial fast release of drug 
(within 4 h) for first four cases (A to D) decreased (A: 52.0 ± 5.5% to D: 15.6 ± 3.7% within 4 h) 
drastically with an increase of diffusional barrier from 0.5 ml to 2 ml in both sides of the core 
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layer. On the other hand the core layer has gradually decreased (4 ml to 1 ml) affecting overall 
release profile particularly for case D. Therefore, we have combined both A and D formulations 
to design a new formulation E (total solution 8 ml) shown in Table 1 and Fig. 2. Thus, the new 
formation E consists of 4 ml core layer similar to sample A and 2 ml barrier layers from both 
sides similar to sample D.  More control on the mobility of drug molecules was noticed with this 
newly fabricated sample E. From Fig. 3a, it can be observed that case E has much control in 
initial release during first 4 h with an appreciable overall release in 24 h. Further to fine tune the 
initial fast release of the drug molecules, additional barrier layers were added to sample E, which 
has resulted  in the fabrication of sample F shown in Table 1 and Fig. 2. In that case, a total 10 
ml of polymer solution was deposited to fabricate the membrane with enough drug loaded core 
(4 ml) and good diffusional barrier (3+3 ml) to control the release profile (Sample formulation: 
F). Release profile (Fig. 3a) for sample F exhibited a good control over the mobility of drug 
molecules and showed a sustained drug release (22.5 ± 6.5% in initial 4 h; total 55.9 ± 2.9 % in 
24 h). Thus further investigation was done with sample F to check the effect of pH (pH 1.2, 6.8 
and 7.4; similar pH profile of human GI tract) and the effect of drug concentration (1.5, 2, 2.5, 
and 3.5 mg/ml) on release profiles.   
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Fig. 3: a) In-vitro cumulative release of piperine from different composition of sandwiched 
membranes. b) Cumulative release of piperine from F sample with different drug concentration 
(1.5, 2, 2.5, 3.5 mg/ml) at pH 1.2 for 4 h, then pH 6.8 for 4 h and finally pH 7.4 for 16 h. (results 
represented are mean ± SD , n=3) 
 
(b) Effect of pH and drug concentration on release profile 
To modify our selected vehicle F based on the results discussed above, the in-vitro system was 
designed in such a way so that the vehicle could be exposed to different pH with different 
retention time, as similar to GI tract [23]. The intension of the design such in-vitro system was to 
understand the effect of swelling and degradation of the vehicle during drug release. Effect of pH 
on the release of piperine from sample F with different drug concentration (1.5, 2.0, 2.5 and 3.5 
mg/ml) was showed in Fig. 3b. The release of drug molecules is accelerated with increase in pH 
for all the cases.  This accelerated release can be explained by the increase in swelling degree in 
higher pH. In higher pH, all the –COOH groups present in gelatin converts into –COO- which 
results high anion-anion repulsion and thus high swelling of the polymer matrix. But in acidic pH 
(<5), due to the high ionic strength of medium, most of the carboxylate groups are protonated 
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and the anion-anion repulsion force are minimized [28]. Additionally, the hydrogen bonding 
between carboxylate and hydroxyl group is also strengthen, which causes overall shrinkage and 
lesser swelling in acidic pH. Thus, swelling capability increases gradually with increase in pH 
which promotes better drug release in higher pH conditions [23]. This phenomena can help to 
minimize the drug loss in lower pH of GI tract (pH of stomach is 1.2 and retention time is 
approx. 4 h) and can effectively swell as well as deliver maximum drug in higher pH region (pH 
of different parts of intestine are 6.8 and 7.4 respectively). Fig. 3b reveals that the drug loading 
in core layers is proportional with drug release. Thus increase in initial drug release within 4 h is 
observed with higher drug concentration in core layers: 6.0 ± 1.2%, 8.4 ± 1.1%, 10.3 ± 0.5%, and 
24.5 ± 2.3% of cumulative release for 1.5, 2.0, 2.5 and 3.5 mg/ml respectively. The F sample 
with 3.5 mg/ml drug concentration didn’t seem to be promising to reach zero order drug release 
due to initial fast release compare to other samples. Although, the highest loaded sample showed 
initial rapid release of drug within 4 h, we have selected the vehicle for further modification in 
order to overcome the drawback associated with burst release while still maintaining the higher 
drug concentration. Our objective is to simultaneously reduce drug loss in stomach (pH 1.2) 
within initial hours (approx. 4 h) and to release drug molecules in the intestine (absorption site) 
in a zero order manner with F sample with highest possible drug loading, i.e. 3.5 mg/ml. In order 
to achieve that, we then worked on another strategy, sequential crosslinking, as discussed further.  
  
(C) Effect of sequential crosslinking on release profile  
We now investigated the effect of different crosslinking methods on the chosen vehicle (3.5 
mg/ml and F type) in order to overcome the limitations of F sample (sudden release in initial 
hours with higher drug loading). Thus, sequential crosslinking of the vehicle was attempted as an 
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additional step. To understand this further, we first deposited the barrier layer of gelatin (3.0 ml) 
nanofibers and then crosslinked it for 2 min with GTA vapor followed by deposition of drug 
loaded core layer (4.0 ml) and again crosslinking for 2 min followed by deposition of only GNF 
(3.0 ml) and then again crosslinking for 2 min. The crosslinking was done sequentially keeping 
the total crosslinking time as 6 min. A comparative study of release profile between sequential 
crosslinked and one time crosslinked sample, both with 3.5 mg/ml F sample, was made in Fig. 
3b. The release of drug from sequential crosslinked sample with 3.5 mg/ml of drug after 4 h was 
less than 10% (7.6 ± 1.8%), whereas one time crosslinking with same drug concentration, the 
initial release within 4h was almost 25% (24.5 ± 2.3%). Results showed sequentially crosslinked 
sample with 3.5 mg/ml of drug successfully toned down the drug loss during initial hours in 
lower pH conditions. At the same time, it showed controlled and sustained release of piperine 
(83.0 ± 4.8% of release after 48 h) for rest of the observation time scale.    
The probable reason of these observations can be understood by the uniformity of crosslinking of 
fibers in-between layers of the mesh while doing it in sequential manner. The compactness of the 
vehicle has increased due to the layer-by-layer crosslinking strategy which also elevated the 
water resistivity degree and restricted the drug molecule mobility [13-15]. Further to understand 
the mechanism of drug release, in-vitro drug release data for sample F with different drug 
loading and different crosslinking strategies were fitted with zero order release and R
2
 values 
were listed. Final design was giving R
2
 as 0.99 for 24 h and 0.97 for 48 h release, which is a 
signature of a zero order case for prolonged time. This has been presented in supplementary 
section (Table 1S and Fig. 5S). Thus it is worthwhile to mention that by doing a systematic 
analysis, the final vehicle design has achieved an optimal performance i.e. much control in initial 
release profile without compromising on overall drug release along with important aspects like 
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stability and less release in lower pH as well as desired zero order release profile in higher pH 
condition for 48 hours using a very cheap biopolymer gelatin based nanofibers. 
 
4. Conclusion: 
Biodegradable polymer mesh was fabricated by electrospinning of natural polymer 
gelatin solution with different concentration of drugs for the assessment of a polymeric 
drug delivery system with hydrophobic drug molecules.  In order to get close to zero 
order drug release, multi-layered membranes with different drug concentrations and 
different crosslinking strategies were applied. The effect of crosslinker was investigated 
in terms of degradation, swelling, chemical stability and thermal stability. Finally, in-vitro 
release study of the vehicle was done in different physiological conditions mimicking the 
pH profile of GI tract. In order to control the initial fast release, different combinations of 
multi-layered membranes were fabricated and studied. As a next step, by modifying the 
core as well as the barrier layer and the crosslinking methods, we have demonstrated that 
one can fabricate electrospun nanofiber mesh which can exhibit better control over the 
initial fast release of a hydrophobic drug in a substantial level and can achieve close to 
zero order release profile for 48 h with flexibility to vary drug loading as per the 
therapeutic requirements. This work lays out the possibility of systematic design of 
multilayer nano-fiber mesh of a cheap biopolymer (gelatin) to be used as a drug delivery 
vehicle for hydrophobic drugs with a desired signature of zero order release for long 
hours.  
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Highlights:  
1. Multi-layered electrospun gelatin nanofiber mat was used as a vehicle for drug delivery 
2. Effect of barrier and drug loaded core layer is directly related to release profile. 
3. Sequential crosslinking achieved better uniformity resulting controlling initial burst 
release 
4. Zero release profile of piperine observed up to 48 h at different physiological pH. 
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